Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Second primary malignancy after treatment with ruxolitinib

Francesca Palandri • 16 Jun 2020
EHA 2020
Lymphoma Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Francesca Palandri, PhD, MD, University Hospital, Bologna, Italy, explores the incidence of second primary malignancies after treatment with ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Francesca Palandri

4:08
Ruxolitinib discontinuation syndrome: real-world data
Francesca Palandri • 16 Jun 2020

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals